73 results about "Laryngeal Cancers" patented technology

The invention discloses a cancer pain-relieving plaster prepared by a preparation A and a preparation B, wherein the preparation A is prepared by five branches, five skins, one brick, one stone, five cores, and the like; the preparation B is prepared by poria cocos, pinellia ternate, jackinthepulpit tuber rhizome, trichosanthes kirilowii maxim, centipede, zaocys dhumnade, and the like. When the cancer pain-relieving plaster is prepared, the preparation B is added into the preparation A to be decocted for 4.5-5.5 hours, red lead is added to be mixed to pasty fluid, then cold water is added for steeping to releasing fire-toxin, water is changed once one day, and the plaster is obtained after steeping for 7 days. When the plaster is used, the plaster is coated on cotton cloth or plaster paster. The cancer pain-relieving plaster mainly aims at tumour cancers of lung cancer, gastric cancer, liver cancer, pancreatic cancer, colon caner, rectal caner, kidney cancer, bladder caner, breast cancer, cervical cancer, ovarian cancer, esophagus cancer, laryngeal cancer, and the like and is obvious in pain-relieving effect.

The invention discloses a water-soluble fullerene nano-material as well as a preparation method and an application thereof. A general structural formula of the water-soluble fullerene nano-material is shown as C2n(OH)x(Amino Acid)y, wherein n is less than or equal to 60 and is greater than or equal to 20, x is less than or equal to 50 and is greater than or equal to 0, y is less than or equal to 20 and is greater than or equal to 0 and Amino Acid is water-soluble amino acid. The nano-material provided by the invention is applied to preparation of medicines for treating tumors, wherein the tumors include at least one of liver cancer, lung cancer, colorectal cancer, renal cancer, pancreatic cancer, cancer in bones, breast cancer, ovarian cancer, prostatic cancer, esophagus cancer, gastric cancer, oral cancer, nose cancer, laryngeal cancer, cancer of biliary duct, cervical cancer, uterine cancer, testicle cancer, meningeoma, skin cancer, melanoma and sarcoma. The nano-material profvided by the invention is good in water solubility, good in affinity with organisms and low in preparation cost, and the nano-material can obviously block off tumor vessels and rapidly cut off nutrition supply to tumor tissues.

Production of medicinal component snow bile pigment and its usage for preparing medicines in treatment of cancers are disclosed. The process is carried out by taking snow bile plant tuber, crushing, taking acetone 18-26 proportion as solvent, extracting by diacolation method, recovering extract in water-bath kettle at 60-75 degree to obtain extractive, adding extractive into silica gel 1-2 proportion, drying to obtain silica-gel column, gradient eluting by ethanol or chloroform with volume concentration 2-10%, recovering eluent to obtain coarse product, heating while dissolving for ethanol or alcohol in water bath, filtering, lowering to room temperature, re-crystallizing to obtain prism crystal with purity above 98%. It can be used to prepare medicines in treatment of hepatocarcinoma, lung cancer, gastric carcinoma, laryngeal cancer and leukemia.

The invention belongs to the technical field of cell research, and particularly relates to a method for constructing a laryngeal cancer cell line for stably expressing the green fluorescent protein. The method comprises the following steps: (1) designing and synthesizing a primer; (2) digesting the gene sequence of pLenti-puro carrier plasmids with BamHI and XhoI according to the gene sequence andpLenti-puro sequence of the green fluorescent protein, and connecting digested products to obtain a target carrier pLenti-puro-GFP; (3) verifying the carrier pLenti-puro-GFP with endotoxin extraction, digesting the pLenti-puro-GFP plasmids with BamHI and XhoI, and detecting the gene sequence by agarose gel electrophoresis, and sequencing the carrier pLenti-puro-GFP plasmids to detect the sequencesituation of the GFP-LC3; and (4) co-transfecting a 293T cell with the carrier pLenti-puro-GFP plasmids and a lentivirus package carrier, collecting virus supernatant, and transfecting a laryngeal cancer cell Hep-2 with the virus supernatant, infecting for 24 hours, then adding a culture medium containing puromycin, screening the cell, and observing under high content until a stable strain is obtained.

The invention discloses a nucleic acid kit for identifying laryngeal cancer cells. The kit comprises a kit body, a temperature control device is installed on the kit body, the upper end of the kit body is provided with a plurality of slots, and one end of a first inserted link is inserted into the slot. The first inserted link is inserted into the slot and a clamping plate passes over a sealing pad so that the leakproofness between a cover plate and the kit body is guaranteed and the normal work of the device is guaranteed. Through the temperature control device, a temperature switch is turnedon, through adjustment of a sliding varistor, the current passing through a heating wire is changed so that the temperature of the heating wire is changed, through a passthrough effect of a through pipe, the work temperature of the kit body can be changed according to demands so that the device can satisfy various operation environments, and a first permanent magnet and a second permanent magnetattract each other so that a pull plate tightly contacts with a rubber pad and thus a support plate is easy to plug and draw and the sealing property of the kit body is guaranteed.

The invention discloses a radiotherapy-targeted sensitizer, comprising the following seven miRNAs: an hsa-miR-138-2-3p stimulant, an hsa-miR-208b-3p stimulant, an hsa-miR-197-3p inhibitor, an hsa-miR-20b-3p inhibitor, an hsa-let-7a-5p inhibitor, an hsa-miR-16-1-3p inhibitor and an hsa-miR-21-5p inhibitor. The invention provides a novel radiotherapy-targeted sensitizer, which is capable of enhancing the radiosensitivity and is small in toxic and side effects, is especially applied to laryngeal cancer patients at various stages, and has an important application prospect. The novel radiotherapy-targeted sensitizer disclosed by the invention is expected to play a great role in improvement of the radiosensitivity and further increase of the curative effect, and good economic and social benefits are generated.

The present invention relates to the use of a compound of formula 3 or a salt thereof to prepare a medicament or phototherapeutic agent for treating the following diseases, including: acne; AIDS; viral hepatitis; diabetic retinopathy; SARS virus infection; coronavirus Arterial stenosis; carotid artery stenosis; intermittent claudication; Asian (chicken) avian influenza virus infection; cervical dysplasia or various cancers, including: blood cancer, cervical cancer, nasopharyngeal cancer, tracheal cancer, laryngeal cancer, bronchial cancer , bronchiolar cancer, bladder cancer, esophageal cancer, stomach cancer, rectal cancer, colon cancer, prostate cancer, hollow organ cancer, bile duct cancer, urinary tract cancer, kidney cancer, uterine cancer, vaginal cancer and other gynecological adnexal cancer. The present invention also relates to methods of treating the above diseases. The present invention further relates to the use of the compound of formula 3 or a salt thereof to prepare a photodiagnostic agent for detecting the above-mentioned diseases and the following diseases, including: atherosclerosis, multiple sclerosis, diabetes, arthritis, rheumatism Arthritis, fungal infections, viral infections, chlamydial infections, bacterial infections, or parasitic diseases, HIV viral infections, hepatitis, herpes simplex, shingles, psoriasis, cardiovascular disease, and skin diseases. The present invention also relates to methods for detecting the above diseases using photodiagnostic agents. The present invention further relates to a method for low-temperature sterilization of surgical devices or other devices, including the steps of: providing a compound of Chemical Formula 3 or a salt thereof on the device; and subjecting the device to radiation treatment or sonication treatment. The invention further relates to a compound of formula 3 or a salt thereof linked or attached to a magnetic element. This compound acts as an MRI enhancer. The invention also relates to the use of such MRI enhancers for performing MRI scans.

The invention discloses anti-cancer medicinal liquor as well as a preparation method and application thereof. The anti-cancer medicinal liquor is prepared from the following raw materials in parts by weight: 350-450 parts of Blaps rynchopetera Fairmaire, 450-550 parts of Tenebrio molitor, 250-350 parts of myrmeleontidae larva, 100-200 parts of Scoropendra subspinipes mutilans and 4500-5500 parts of Baijiu. After being reasonably drunk, the anti-cancer medicinal liquor has a remarkable curative effect on laryngeal cancer, rectal cancer, breast cancer, gastric cancer, bladder cancer, prostate cancer, uterus cancer and the like; the anti-cancer medicinal liquor can effectively slow down the deterioration of diseases and alleviate symptoms, and also can effectively reduce surgical injury to patients who are subjected to operations and chemoradiotherapy, improve immunologic cellular activity inhibited by the chemoradiotherapy, consolidate the curative effect of the chemoradiotherapy and reduce the toxic and side effects of the chemoradiotherapy, thus effectively improving the survival quality of the patients and prolonging the lives of the patients.

Provided herein are methods for detecting a head and neck cancer of the oral cavity or throat, optionally oral squamous cell carcinoma, comprising executing the step of determining the expression of two or more miRNA in a biological sample obtained from a subject, wherein the two or more miRNA are selected from the group consisting of hsa-let-7a, hsa-miR-16, hsa-miR-21, hsa-miR-451, hsa-miR-486-5p and hsa-miR-92a-3p, and wherein the level of expression of said two or more miRNAs in the biological sample relative to the level of expression of said two or more miRNAs in one or more cancer-free reference samples is indicative of the presence of a head and neck cancer of the oral cavity or throat of the subject.

The invention discloses application of sophora tonkinensis gapnep lupanol, and particularly discloses application of the sophora tonkinensis gapnep lupanol to preparation of medicinal preparations fortreating tumors. The sophora tonkinensis gapnep lupanol provided by the invention has very good antitumor activity, can significantly inhibit growth of nasopharyngeal cancer cells, cervical cancer cells, esophageal cancer cells, liver cancer cells, laryngeal cancer cells, breast cancer cells and prostate cancer cells and inhibit metastasis of the nasopharyngeal cancer cells, and has a good application prospect in development into medicines for treating nasopharyngeal cancer and other diseases.

The invention relates to a method for determining and screening differential metabolites of laryngeal cancer serum based on an inverted phase chromatography time-of-flying mass spectrum. The method is characterized by comprising the steps of settling protein from serum by virtue of an organic solvent, namely methanol, carrying out centrifugation and vacuum centrifugal drying, redissolving the serum into 200 microliters of pure water, introducing the solution into an inverted phase chromatography time-of-flying mass spectrometer for determination, and carrying out peak alignment, correction and standardization, multivariate statistics analysis and spectrum library searching, so as to find differential metabolites in serums of laryngeal cancer volunteers and healthy volunteers. The method is a brand-new method for identifying the differential metabolites in the serum, and the variation conditions of the serum metabolites of laryngeal cancer patients can be reflected by the differential metabolites, so that the method will contribute to the diagnosis, clinic treatment and prognosis of the laryngeal cancer and the research of pathogenesis of the laryngeal cancer.

The invention provides a traditional Chinese medicine preparation and for main treatment of esophagus cancer and a preparation method thereof, and the traditional Chinese medicine preparation is prepared by selection of pearl, ginseng, calculus bovis, bear gall, borneol, stiff silkworm, house lizard, centipede, pseudo-ginseng, menthol, cinnabar, borax, smoked plum, propolis, tendril-leaved fritillary bulb, ephedra, pinellia tuber, scutellaria barbata and other medicinal materials. The traditional Chinese medicine preparation has the main effects of downbearing counterflow and checking vomiting, eliminating phlegm and detoxifying, softening hardness and dissipating stasis, transforming putridity and promoting tissue regeneration, dredging esophagus, relieving pain, and suppressing and resisting cancer. The traditional Chinese medicine preparation has good effects on esophageal discomfort, dysphagia, esophageal stenosis and obstruction caused by early and middle-late esophageal cancer, can kill cancer cells and inhibit the growth of the cancer cells, prevents the spread of the cancer cells, improves microcirculation, can be used for spasmolysis of smooth muscle so as to inhibit cancer cell growth and metastasis, is mainly used for esophageal cancer, also has certain curative effect on cardiac cancer, gastric cancer, ingluveosis phrenospasm, laryngeal cancer, lung cancer, liver cancer, breast cancer, pancreatic cancer, cervical cancer, intestinal cancer, esophagitis, various kinds of pharyngolaryngitis and the like.

The invention relates to new application of cucurbitacin in the preparation of a medicament for treating cancer and relates to application of the cucurbitacin in the preparation of a medicament for treating the laryngeal cancer.

Disclosed are increased expression of ERp57, ERp57-STAT3 complex, and ERp57-STAT3-Mcl-1 in laryngeal cancer, especially in radioresistant laryngeal cancer and their regulations on radioresistance of laryngeal cancer. As such, the efficacy of radiotherapy can be enhanced by diagnosing prognosis in laryngeal cancer and radioresistance of laryngeal cancer. Furthermore, provided are a method of screening a therapeutic agent for laryngeal cancer including selecting a candidate drug that inhibits the expression of ERp57 or inactivates ERp57, and a therapeutic method for inhibiting or treating laryngeal cancer or radioresistant laryngeal cancer, thereby being useful in the treatment of laryngeal cancer.

The invention relates to a chemotherapy-type anticancer drug inhalation powder preparation and a preparing method and application thereof. According to the technical scheme, the chemotherapy-type anticancer drug inhalation powder preparation is obtained by mixing effective constituent powder with the grain diameter being 0.4-5 microns or 10-100 microns and carrier powder with the grain diameter being 10-100 microns. The effective constituent powder comprises a chemotherapy-type anticancer drug and Omega-3 fatty acid. The carrier powder comprises saccharides, an emulsifier and magnesium stearate. The application effect of the preparation in treatment of respiratory system cancers like a laryngeal cancer, a lung cancer and other tumor diseases is obvious. The inhalant form toxicity is small, the application is convenient, and the anticancer treatment effect has advantages compared with other dosage forms.

The invention discloses a snake poison cytotoxin, the preparation method and the application. The method of preparing the snake poison cytotoxin in the invention includes the following steps: firstly, the snake poison is conducted an ion-exchange chromatography and then the eluent between a first absorption peak and a second absorption peak on the absorbance curve with a detection wavelength of 280nm in the eluent is gathered; secondly, the eluent obtained in the first step is conducted an exclusion chromatography, water is used as a moving phase, and the second absorption peak on the absorbance curve with a detection wavelength of 280 nm in the eluent is gathered to obtain the snake poison cytotoxin. The saw-scale viper poison cytotoxin in the invention can induce the human laryngeal cancer cell Hep-2 to an apoptosis and the capability of inducing Cell Hep-2 to an apoptosis is stronger than Pingyangmycin with a viscosity of 100 Mug / ml when the snake poison cytotoxin has a concentration of 0.01 mg per milliliter. In addition, experiments of undue toxicity prove that the cytotoxin has slight side effects. The saw-scale viper poison cytotoxin in the invention can be used as an anti-cancer drug to turn biological anti-cancer drugs into a reality.

The invention provides application of doxycycline in preparing antitumor drugs, wherein the tumor contains one or a combination of more of tongue cancer, laryngeal cancer, choriocarcinoma, sialaden tumor, gallbladder carcinoma and thymoma. In the application, doxycycline can be used as the drug for inhibiting tumor growth as well as the drug for inhibiting tumor metastasis. The drug can be easilyaccepted by patients, is low-cost, is extensive in source, can be easily acquired and is convenient for understanding the reaction of patients to the drug. Besides, doxycycline will change the existing market structure of tumor chemotherapeutic drugs and can become a clinical drug suitable for long-term administration and capable of effectively inhibiting tumor metastasis, invasion and relapse.

The invention provides anti-cancer and cancer-preventing health-care medicated wine. The anti-cancer and cancer-preventing health-care medicated wine is prepared from the following raw materials in parts by weight: 10 to 16 parts of glossy privet fruit, 13 to 17 parts of Chinese date, 12 to 18 parts of medulla tetrapanacis, 8 to 12 parts of asparagus, 2 to 4 parts of herba epimedii, 16 to 20 partsof radix celastri orbiculati, 14 to 18 parts of herba hedyotidis diffusae, 18 to 22 parts of lucid ganoderma, 3 to 5 parts of longan aril, 12 to 16 parts of herba cistanche, 15 to 17 parts of herba sculellariae barbatae, 4 to 8 parts of Chinese euroleon, 2 to 4 parts of smelly shell worm, 16 to 20 parts of herba rhodiolae, 2 to 6 parts of radix ginseng, 17 to 23 parts of manis pentadactyla, 11 to15 parts of sea horse and 100 to 160 parts of high-alcohol-content rice wine. The anti-cancer and cancer-preventing health-care medicated wine adopts pure natural plant materials, does not have any side effect, is reasonable to take, has remarkable curative effect on laryngeal cancer, breast cancer, rectal cancer, gastric cancer, liver cancer, bladder cancer, prostatic cancer, uterine cancer andthe like, effectively inhibits the deterioration speed of the disease state, alleviates symptoms, can effectively reduce surgical injury to patients subjected to surgery as well as radiotherapy and chemotherapy, and can improve the immune cell activity inhibited by radiotherapy and chemotherapy.

The invention provides a pharmaceutical composition and an application thereof, wherein the pharmaceutical composition consists of oridonin and cetuximab. The pharmaceutical composition, when used fortreating laryngeal cancer, shows an obvious synergistic effect. Based upon both in-vivo and in-vitro experiments, it is proved that the pharmaceutical composition provided by the invention can obviously inhibit the growth of laryngeal cancer cells, and the pharmaceutical composition is subjected to a mechanism of inhibiting the activation of an EGFR signaling pathway; and meanwhile, the pharmaceutical composition can promote the generation of reactive oxygen so as to induce apoptosis of the laryngeal cancer cells and cell cycle arrest. The pharmaceutical composition provided by the invention,when used for treating the laryngeal cancer, has the advantages of being obvious in antineoplastic effect and low in toxic and side effects.

The invention relates to a medicament for treating cancer diseases, which comprises toad venom, blister beetle, honeycomb, long-noded pit viper, typhonium giganteum and langdu root. A preparation method for the medicament comprises the following steps: taking a right amount of the raw materials; hitting the raw materials into powder; adding a small amount of honey into the powder; and uniformly stirring the mixture to prepare 0.5 gram of water-honeyed pill. The medicament is used for treating malignant tumors, such as esophagus cancer, laryngeal cancer, stomach cancer, lung cancer, pancreatic cancer, mastocarcinoma, liver cancer and the like. The user respectively takes 3 pills of the medicament in the morning and in the evening. The weak patient takes one pill every two hours and is treated according to the course of treatment. Each course is one month. The effect of the medicament is more ideal. The serious patient need 7 to 10 courses of treatment, while the mild patients need 4 to 6 courses of treatment. The consolidating effect is the best when the medicament is used after the operation.